arrow
B

Brigitte Pan-Petesch

CHU Brest and Université de Brest
H指数:17
被引数:1,509

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Superficial Vein Thrombosis During Pregnancy and Postpartum—Findings From the French Multicenter Cohort “HEMOTHEPP” Study

妊娠期及产后浅静脉血栓形成——来自法国多中心队列“HEMOTHEPP”研究的结果

2026-09-210
OAAI
Short- and long-term outcome of neonates with thrombocytopenia from maternal immune thrombocytopenia

母婴免疫性血小板减少症患儿的短期和长期预后

2026-03-110
OAAI
Unmet needs despite standard-of-care prophylaxis in hemophilia A: improved outcomes after switching to efanesoctocog alfa

尽管标准护理预防措施,血友病A中未满足的需求:转为使用efanesoctocog alfa后结局改善

2026-01-010
OA
Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms

鲁索利替尼和羟基脲是真实世界研究中骨髓增殖性肿瘤患者减轻水诱性瘙痒强度的最有效药物。

2025-12-010
OAAI
F8 gene variants influence the response to desmopressin in hemophilia A carriers

F8基因变异影响血友病A携带者对去氨加压素的反应

Blood
IF23.1
2025-08-250
PRE
Health-related quality of life in children with von Willebrand disease: results of the French real-life Willebrand Study Health-related Quality of Life study

von Willebrand病患儿的健康相关生活质量:法国真实生活Willebrand研究健康相关生活质量研究的结果

2025-05-270
OAAI
Impact of Systematic Joint Examination (Ultrasound, Functional and Physical) on Treatment Management Decisions in Patients With Haemophilia A in France: Final Data From the Prospective, Observational A-MOVE Study
2025-02-010
OAAI
Efficacy and safety of dapsone in adult primary immune thrombocytopenia

达拉菲的疗效和安全性:用于成人原发性免疫性血小板减少症

2025-01-280
OA
Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs
2024-10-011
PRE
Family history of postpartum hemorrhage is a risk factor for postpartum hemorrhage after vaginal delivery: results from the French prospective multicenter Haemorrhages and Thromboembolic Venous Disease of the Postpartum cohort study

产后出血家族史是阴道分娩后产后出血的危险因素: 法国前瞻性多中心产后出血和血栓栓塞性静脉疾病队列研究的结果

2023-09-014
OAAI